Special Issue

Artificial Intelligence in Vaccine Design

Message from the Guest Editors

In last decade, the areas of data science, informatics, and artificial intelligence (AI) have all experienced great expansion. Machine learning-based (ML) models have provided quick and affordable ways to find efficient treatments and bioinformatics has changed immunology research leading to the discipline of immunoinformatics, in particular in field of infectious disease and virus. The aim of this Special Issue is to bring tools, methods, approaches and potential agents that will provide with new insights for developing new strategies for vaccine or its adjuvant. Experimental papers, review articles and commentaries are all welcome.

Guest Editors

Dr. Paolo Coghi

Dr. Xingxing Fan

Dr. Alex Po Leung

Deadline for manuscript submissions

closed (30 December 2023)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/135415

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/ vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

